- Home
- SBFM vs ARTL Comparison
SBFM vs ARTL Comparison
Compare SBFM & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- ARTL
- Stock Information
- Founded
- SBFM 2006
- ARTL 2011
- Country
- SBFM United States
- ARTL United States
- Employees
- SBFM N/A
- ARTL N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- ARTL Health Care
- Exchange
- SBFM Nasdaq
- ARTL Nasdaq
- Market Cap
- SBFM 6.7M
- ARTL 7.0M
- IPO Year
- SBFM N/A
- ARTL N/A
- Fundamental
- Price
- SBFM $1.67
- ARTL $4.46
- Analyst Decision
- SBFM Strong Buy
- ARTL Buy
- Analyst Count
- SBFM 1
- ARTL 2
- Target Price
- SBFM $15.00
- ARTL $30.00
- AVG Volume (30 Days)
- SBFM 62.2K
- ARTL 86.0K
- Earning Date
- SBFM 11-04-2025
- ARTL 11-11-2025
- Dividend Yield
- SBFM N/A
- ARTL N/A
- EPS Growth
- SBFM N/A
- ARTL N/A
- EPS
- SBFM N/A
- ARTL N/A
- Revenue
- SBFM $36,341,741.00
- ARTL N/A
- Revenue This Year
- SBFM $32.20
- ARTL N/A
- Revenue Next Year
- SBFM $32.74
- ARTL N/A
- P/E Ratio
- SBFM N/A
- ARTL N/A
- Revenue Growth
- SBFM 19.22
- ARTL N/A
- 52 Week Low
- SBFM $1.17
- ARTL $4.20
- 52 Week High
- SBFM $3.90
- ARTL $28.60
- Technical
- Relative Strength Index (RSI)
- SBFM 67.82
- ARTL 34.64
- Support Level
- SBFM $1.50
- ARTL $4.29
- Resistance Level
- SBFM $1.67
- ARTL $4.93
- Average True Range (ATR)
- SBFM 0.08
- ARTL 0.42
- MACD
- SBFM 0.01
- ARTL 0.07
- Stochastic Oscillator
- SBFM 73.44
- ARTL 6.42
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.